Deals Of The Week: Charles River/WuXi, Aton/Bristol, Merck/Nycomed ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com
You may also be interested in...
Charles River-WuXi PharmaTech Deal Transforms China's CRO Landscape
Charles River's acquisition of WuXi PharmaTech, valued at $1.6 billion, is the largest merger so far in China's healthcare space and is likely to drastically change the CRO playing field in China
Aton Pharma Moves Beyond Its Merck Connections With Pick-up From Bristol
Specialty pharma focuses on acquiring marketing rights to mature products underappreciated in their market areas.
Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe
Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit